Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14646202 | 0.99 | DPP4 (0.45) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL352568 | 0.94 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL14646178 | 0.93 | ALDH1A1 (0.40) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL15695322 | 0.91 | ALDH1A1 (0.42) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL9976555 | 0.91 | DPP4 (0.40) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL14645356 | 0.91 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL9976554 | 0.91 | DPP4 (0.40) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL13421967 | 0.89 | ALDH1A1 (0.38) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL17803966 | 0.87 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1KDM4EDPP4 | |
| SCHEMBL17803941 | 0.87 | ALDH1A1 (0.39) | ALDH1A1KMT2AMEN1KDM4EDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350042-B1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPHY | CPL BCX PHARMA AB (SE) | 2015-07-29 | — | — | EP | disclosed |
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-8710246-B2 | Substituted thiophene pentamers | BIOCHROMIX NEWCO AB (SE) | 2014-04-29 | — | — | US | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | BIOCHROMIX PHARMA AB | 2012-06-21 | — | — | US | disclosed |
| WO-2010044744-A1 | NOVEL THIOPHENE COMPOUNDS FOR IN VIVO IMAGING | BIOCHROMIX AB (SE) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010044743-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPHY | BIOCHROMIX PHARMA AB (SE) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157516-A1 | NOVEL THIOPHENE COMPOUNDS FOR USE IN THERAPY | HSPE1, TTR, HTT | ALDH1A1 3577/4885KMT2A 4559/4885MEN1 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.